First Tracks surges on positive results from celiac disease drug trial (October 12)

** Shares of biotechnology company First Tracks Biotherapeutics TRAX.O soar 16.2% to $37 premarket

** Co announces positive top-line results for its drug, ANB033, in gluten-challenge study in celiac disease

** ANB033 is co's experimental antibody drug to treat autoimmune and inflammatory diseases, including celiac disease

** Celiac disease is an autoimmune condition in which eating gluten damages the small intestine

** TRAX says ANB033 limits symptoms worsening during 14 days of gluten consumption

** Reports ANB033 was well tolerated, with no serious adverse events

** Expects top-line data from Cohort 2 of its ANB033 celiac disease trial in Q1 2027 and eosinophilic esophagitis trial in Q3 2027

** Expects to start Phase 2 development of ANB033 in vitiligo and another indication in H1 2027

** TRAX shares have nearly doubled since their Nasdaq debut in April after being spun out of AnaptysBio ANAB.O